Discover how Riley Children's BDP program is improving outcomes for premature babies at risk of severe bronchopulmonary dysplasia (BPD). Learn more here.
Compared to placebo, high-dose recombinant human erythropoietin within 2 days of life does not improve neurodevelopmental outcomes for preterm infants.